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1. Introduction  
1.1 Pancreatic cancer 
Pancreatic ductal adenocarcinoma (PDAC) is the most (95%) common 
pancreatic neoplasia. PDAC is a very deadly disease that is characterized by 
late diagnosis with high incidence of metastases and therefore limited 
treatment options [1]. 
1.1.1 Incidence, Mortality and Survival 
The incidence rate of PDAC varies between different countries due to variable 
risk factors like lifestyle factors, such as diet, or environmental factors. There 
are more male patients diagnosed with PDAC compared to female (Figure.1) 
[1]. The incidence of PDAC is constantly rising, especially in North America [2], 
Europe and Japan [3] as well as in China. In the United States (US), PDAC 
represents the fourth and in Europe the fifth most frequent cause of death from 
cancer [4]. In 2008, an estimated incidence of PDAC in the US was 37,700 and 
279,000 worldwide (Cancer Research UK, 2011). In China, the estimated 
number of newly diagnosed PDAC cases and deaths were 80,344 and 72,723 
in 2011, respectively [5]. The overall five-year survival rate of PDAC patients is 
less than five percent [6]. At the time of diagnosis, only 10-20% of patients 
have resectable PDAC [7]. In the US the median age at diagnosis of PDAC is 
72 years and, rates are strongly age-dependent. Only about 5-10% of patients 
develop PDAC before the age of 50 years [1]. Median survival rate of the 
patients after the surgery ranges from 13 to 21 months and for patients without 
surgery, the median survival is between 2.5-8 months. Recently, a group from 
the US showed that patients with high risk of early mortality after surgical 
resection of PDAC can be identified using simple baseline clinical and 
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laboratory parameters. Future studies should address preoperative 
interventions in these patients at high risk of early mortality [8]. 
 
  
 
Figure.1 Global age-standardized incidence rates of PDAC in men  
Data from the International Agency for Research on Cancer based on countries with >100 
PDACs [1]. 
1.1.2 Risk Factors 
Only a few demographic, environmental risk factors and a few genetic 
autosomal dominant disorders are known to be associated with PDAC. The 
further risk factors associated with PDAC development are as follows: 
 
1.1.2.1 Smoking 
Schulte et al. [9] reported that both smoking intensity and smoking duration 
were found to be associated with increased risk of PDAC, but smoking 
intensity is less important than duration or time since quitting. One 
 11 
meta-analysis showed evidence of non-linear association between smoking 
intensity and PDAC risk, might differ between sexes [10]. Some mitotic 
regulator genes might be the potential molecular mediator behind 
smoking-associated PDAC [11]. 
 
1.2.1.2 Diabetes 
Diabetes is another risk factor for PDAC development. Tumorigenesis 
of PDAC and the pathophysiology of type II diabetes mellitus (DM2) are 
emerging as intertwined pathways. DM2 suggests pancreatic dysfunction and 
possible an early risk factor for PDAC [12]. Patients with type I diabetes (DM1) 
or early onset of diabetes have a double risk for PDAC development [13]. 
Furthermore, Austin et al. reported that also family history of diabetes was 
associated with increased risk of PDAC [14]. 
 
1.2.1.3 Obesity 
A meta-analysis of 6391 patients with PDAC found a relative risk of 1.19 for 
cancer among obese persons, compared with persons of normal weight [15]. 
The available data for obesity are convincing, and reinforce the concept that 
maintaining a healthy body weight can prevent PDAC. 
 
1.2.1.4 Pancreatitis 
Another known risk factor is pancreatitis, especially chronic pancreatitis [16]. A 
recent meta-analysis including 22 studies found an increased relative risk of 
developing PDAC of 5.1 in patients with unspecified pancreatitis, 13.3 in 
patients with chronic pancreatitis and 69 for hereditary pancreatitis with a 
lifetime risk of 40–55% [17].  
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1.2.1.5 Other factors  
Other risk factors include family history, advancing age, male gender, non-O 
blood group, occupational exposures (eg, to chlorinated hydrocarbon solvents 
and nickel), African-American ethnic origin, and possibly Helicobacter pylori 
infection and periodontal disease [1]; [18];[19];[20]. 
1.1.3 Symptoms and Diagnosis of PDAC 
PDAC is generally known as a clinical silent disease in its early stages. It often 
grows and metastasizes without significant symptoms which make it difficult for 
early diagnose. Clinically, the main symptoms of PDAC include indigestion, 
nausea, weight loss, jaundice, steatorrhea, abdominal and/or back pain. 
However, patients with PDAC are often asymptomatic. Jaundice and 
abdominal pain may occur in the progressive stage of PDAC, whereas some 
nonspecific symptoms, such as indigestion and weight loss, are easily 
mistaken for other diseases. Regarding this situation, the majorities of patients 
have the median tumor size about 3.1 cm at the time of diagnosis and and thus 
reduces the chances of curative surgical resection of the tumors [21]. Although 
initial diagnosis become more important for the patients, but still it remains to 
be one of the greatest challenges in the fight against cancer in the 21st century. 
Now available pancreatic imaging has a key role in the characterization of 
pancreatic focal lesions, initial staging, surgical plan, and assessment of the 
treatment response using various imaging modalities, including computer 
Tomography (CT), endoscopic ultrasonography (EUS), Magnetic Resonance 
Imaging (MRI) and Magnetic resonance cholangiopancreatography (MRCP), 
et al. [22]. Meanwhile MRI is commonly used to detect PDAC when a mass 
lesion is not identifiable by CT scan or MRCP [23]. One of the serological 
markers for diagnosis and monitoring of therapy is the tumor marker 
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carbohydrate antigen 19-9 (CA19-9). Carcinoembryonic antigen (CEA) is 
another known marker for diagnosis and monitoring of PDAC [24]. 
 
1.1.4 Treatments of PDAC 
Surgical resection offers hope for curative therapy of PDAC, but only 20% of 
patients present with potentially resectable tumors [25];[26]. Even with surgical 
resection, 5-year survival rates remain dismal, at approximately 20% following 
the surgry [25]. Due to its poor detection rate, 60%-70% of patients present 
with metastatic PDAC upon initial diagnosis. Chemotherapy is the main 
therapy for the advanced disease.Gemcitabine monotherapy became a 
standard first-line treatment option for metastatic pancreatic cancer after it 
demonstrated superior clinical benefit over 5-fluorouracil [27]. It has been 
shown to prolong the average survival rate by 4 months. Renouf et al. [28] 
reported a phase II study of erlotinib in patients with advanced pancreatic 
cancer previously treated with gemcitabine, median survival was 3.8 months 
and 6 month overall survival rate was 32%. Conroy et al. reported that the 
median overall survival was 11.1 months in the FOLFIRINOX group as 
compared with 6.8 months in the gemcitabine group. Median progression-free 
survival was 6.4 months in the FOLFIRINOX group and 3.3 months in the 
gemcitabine group [7]. Goldstein, et al. [29] reported the median overall 
survival was statistically significantly longer for nab-paclitaxel plus gemcitabine 
vs. gemcitabine alone (8.7 vs 6.6 months) for metastatic PDAC patients. In 
general, systemic chemotherapy in PDAC is still limited. 
1.1.5 Carcinogenesis of PDAC 
The classical and well-characterized precursor lesions of PDAC show a ductal 
phenotype, suggesting a ductal cell of origin of this tumor. A major advance in 
the pathological assessment has been in agreement that pancreatic 
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intraepithelial neoplasia (PanIN), mucinous cystic neoplasm [8], and 
intraductal papillary mucinous neoplasm (IPMN) are different precursor lesions 
for PDA (Figure.2). 
 
Figure.2 Pathways of PDAC progression  
These alternate versions of the same medical illustration were created to highlight the 
divergent paths that ductal and acinar cells undergo when developing into the pancreatic 
ductal adinocarcinoma precursers PanIN and IPMN [31]. 
 
In 2003, the first transgenic mouse model that faithfully recapitulates the 
development of PDAC from low-grade precursors to metastatic cancer has 
been generated [32]. PanIN lesions, are classified as PanIN1a, PanIN1b, 
PanIN2, and PanIN3 which are allied with progressive alterations in the nuclei, 
epithelial polarity and architecture, and end in carcinoma in situ state (PanIN3) 
[33]. It has been shown that virtually all PanINs, including more than 90% of 
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low-grade PanINs, harbor mutations in the Kras gene locus, followed 
by CDKN2A/p16, SMAD4 and Tp53 mutations in intermediate and later stages 
of pancreatic carcinogenesis [34]; [35]; [36]. Kras is a 
Guanosine-5'-triphosphate (GTP) -binding protein and belongs to the member 
of the Ras family that facilitates a diversity of cellular functions like 
proliferation, differentiation, and survival [37]. The mutation of oncogene Kras 
can be detected almost 100% in advanced PDAC [38]. In another study, 
mutant Kras in acinar cells resulted in neoplastic lesions in mouse pancreas 
that progressed to PDAC in conjunction with Tp53 deletion [39]. Nuclear factor 
κB (NF-κB) is known to play a key role in inflammation is the transcription 
factor and its activity has also been observed in PDAC tissue. In addition 
to Kras mutations, many genetic mutations are reported in PDAC. Biankin et al 
[16] performed exome sequencing and copy number analysis in a cohort of 
142 sporadic PDAC cases and reported multiple significantly mutated genes, 
including the known mutations- Kras, Tp53, CdkN2A, 
SMAD4, MLL3, TGFBR2, ARID1A, SF3B1 and some gene also play an 
important role in PanIN progression. Abrogation of CdkN2A can occur in 
low-grade or early stage of PanIN, whereas aberrations of Tp53 and SMAD4 
can be detected in high-grade/late PanINs [40]. It is increasingly understood 
that PDAC consist microenvironment composed of dense fibrotic stroma with 
cancer cells, stellate cells, infiltrating inflammatory cells, fibroblasts which are 
responsible for the production of collagen and fibronectin [41]. The tumors also 
consist of cancer stem cells which are thought to be responsible for 
chemotherapy resistance. 
 
Epithelial-to-mesenchymal transition (EMT) is the progression that makes the 
conversion of adherent epithelial cells into independent fibroblastic cells 
possessing migratory properties and the ability to invade the extracellular 
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matrix [42]; [43]. In vitro, various carcinoma cell lines undergo partial or 
complete EMT (Figure.3). Beuran, et al. [44] concluded that there is a strong 
correlation between the EMT and the systemic aggressiveness 
of PDACs. Consequences of the EMT are the loss epithelial marker 
(E-cadherin) expression and the acquisition of mesenchymal markers 
including N-cadherin or Vimentin. Molecular processes underlying 
the EMT have opened possibilities for new therapeutic agents.  
 
Figure.3 Sites of EMT in the emergence and progression of carcinoma 
Normal epithelia lined by a basement membrane can proliferate locally to give rise to an 
adenoma. Further alterations can induce local dissemination of carcinoma cells, possibly 
through an epithelial-mesenchymal transition (EMT). 
1.2 p27kip1 Gene  
Cyclin-dependent kinase inhibitor 1B (p27Kip1) is an enzyme inhibitor that in 
humans is encoded by the CdkN1B gene [45]. p27Kip1 belongs to 
the “Cip/Kip” family of cyclin dependent kinase (Cdk) inhibitor proteins. p27Kip1 
binds to and prevents the activation of cyclin 
E-Cdk2 or cyclinD-Cdk4 complexes, and thus controls the cell 
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cycle progression at G1 phase. It is often referred as a cell cycle inhibitor 
protein. The p27Kip1 gene has a DNA sequence similar to other members of 
the "Cip/Kip" family which include the p21Cip1/Waf1. p27Kip1 is considered a tumor 
suppressor because of its function as a regulator of the cell cycle (Figure. 4). 
p27Kip1 can inhibit or promote cell motility, data increasingly indicate that 
p27Kip1 integrates mechanisms regulating cell proliferation, migration, invasion 
and metastasis.  
 
The Loss of expression or down regulation of p27Kip1 protein can be observed 
in many cancers and is proved to be an independent prognostic factor in these 
malignancies [46]. Juuti et al. showed that loss of p27kip1expression was 
associated with poor prognosis in stage I-II of PDAC; the 5-year survival for 
p27kip1 negative patients was 3.6% compared with 20% for p27kip1-positive 
patients (p= 0.03) [47]; [48]. 
 
 
Figure.4 Cell cycle progression is regulated by cyclin–Cdk complexes  
Schematic diagram shows different classes of Cyclin and Cdk molecules. p27
Kip1
 inhibits the 
catalytic activity of Cyclin E/Cdk2 as well as Cdk4. Increased the level of p27
Kip1 
can cause cell 
to rest in G1 phase of the cell cycle [49] ;[50]. 
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1.3 Argyrin F (AF) 
Nickeleit, et al. [51] identified Argyrin A as a proteasome inhibitor that by 
preventing the destruction of the cyclin kinase inhibitor p27kip1 exerts broad 
antitumoral activities. All antitumoral activities of Argyrin A depend on the 
prevention of p27kip1 destruction, as loss of p27kip1expression confers 
resistance to this compound. Argyrin A has several analogues and AF is one 
of them, it is a chemically synthesized cyclical peptide with potent antitumoral 
activity [52]. Bülow, et al. have tested AF on colon cell lines and find that AF 
treatment resulted in an up-regulation of p27kip1 in SW-480 colon carcinoma 
cells in a dose-dependent manner like Argyrin A, requiring p27kip1 expression 
for the induction of its biological phenotype [52]. They found that AF leads to 
an even faster destruction of blood vessels in vivo compared to Argyrin A 
which increases the ability of AF to reduce the size of solid tumors in mice 
models [52]. Based on these studies, we set out to identify the antitumor effect 
of AF on PDAC. 
                
1.4 Aims of study  
The major aim of the present study is to explore the anti-tumor activity of 
Argyrin F against PDAC.  
1.4.1 Work Program 
- Analysis of cell proliferation and apoptosis under AF treatment 
- Analysis of cell colony formation under AF treatment 
- Analysis of migration and invasion under AF treatment 
- Analysis of cell senescence under AF treatment 
- Analysis of EMT under AF treatment 
- Analysis of cell cycle under AF treatment 
- In vivo therapy of AF and AF+Gemcitabine (G) treatment in a PDAC mouse 
model: analysis of survival, tumor volume, cell proliferation and angiogenesis 
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2. Material and Methods 
2.1 Material 
2.1.1 Expendable items 
Cover slip 
Freezing tube 
Microscope slides 
Transfer membrane 
Hyperfilm TM ECL 
Whatman 
Centrifuge tubes 
Dialysis tubing 
6 wells plate                                                  
12 wells plate                                                
96 wells plate  
Cell culture dishes 1000x15 mm 
Cell culture dishes 60x15 mm 
Micro tube 1,5 ml   
Filter Tips 0,1-10 ul 
Filter tips 20 ul 
Filter tips 200 ul 
Filter tips 1000 ul     
15 ml tube 
50 ml tube                                   
Menzel-Glaeser, Braunschweig 
Sarstedt, Nürnberg 
Menzel-Glaeser, Braunschweig 
Perkin Elmer, Rodgau 
Amersham Bioscience, Braunschweig 
Omnilab, Elbingeröder 
Beckmann, Palo Alto 
Pierce, Rockford 
Sarstedt, Nürnberg
Sarstedt, Nürnberg
Sarstedt, Nürnberg 
Sarstedt, Nürnberg 
Greiner Bio-One, Frickenhausen 
Sarstedt, Nürnberg 
Sarstedt, Nürnberg 
Sarstedt, Nürnberg 
Sarstedt, Nürnberg 
Greiner, Solingen 
Sarstedt, Nürnberg 
Sarstedt, Nürnberg 
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2.1.2 Equipments 
Agarose Gelelectrophoresis systems  
Centrifuges: 
Centrifuge 5415 D 
Centrifuge Mikro 220 R cooled 
Megafuge 1.0 
Centrifuge “Rotina 38R” 
Centrifuge “L8-55M” 
Chaker vibramax 110                   
Clean Bench        
Easypet 4420                
Electrophoresis power supply 
Fluoresence microscope  
Gel chambers for proteins         
Heater     
Incubator                                                
Magnetic stirrers   
MicroPulser TM 
Microtiterplate luminometer  
Microwave   
Mini-Protein Electrophoresis System 
Mini Trans-Blot cell   
Mixer 5432     
Multipette® plus    
pH-meter 
Photometer 
Pipett 
Pipetman 
Bio-RAD,  München 
Eppendorf, Hamburg 
Roth Karlsruhe 
Heraeus, Osterode 
Hettich, Tuttlingen 
Beckman GmbH, Düsseldorf                                                                       
GFL, Burgwedel 
Heidolph, Kelheim 
Hera Safe, Kendro, Osterode 
Sartorius, Göttingen 
Leica DM5000, Leica, Wetzlar 
Bio-RAD, München 
Bio-RAD, München 
Heraeus,Instruments GmbH, Osterode 
Heidolph, Kelheim 
Bio-RAD, München 
Tecan Deutschland GmbH, Crailsheim 
Bauknecht, Stuttgart 
Bio-RAD, München 
Bio-RAD, München  
Bio-RAD, München  
Eppendorf, Hamburg 
InoLab, Weilheim 
Eppendorf, Hamburg 
Eppendorf, Hamburg 
Hirschmann, Eberstadt 
Bio-RAD, München  
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Power supplies    
Sonifier UP 200H                                        
Thermo cycler   
Thermomixer 5436       
ThermoStat plus  
Vortex-Genie           
Water baths                                                              
 
Gilson, Villiers le Bel 
Bio-RAD, München
Hielscher, Stahnsdorf 
MWG-Biotech  AG, Ebersberg 
Eppendorf, Hamburg 
Eppendorf, Hamburg 
Janke & Kunkel, Staufen 
 
2.1.3 Software 
Microsoft Excel 2007 (Microsoft Inc., Remond, Washington, USA) 
Microsoft Word 2007 (Microsoft Inc., Remond, Washington, USA)  
FlowJo Version 7.3 (Tree Star Inc., Ashland, USA) 
BD Cell Quest ProTM (BD Biosciences, Mississauga, USA) 
ImageJ 1.42 (Free Software Foundation, Inc., Boston, USA) 
Adobe Photoshop 7.0 (Adobe Systems, San Jose, USA) 
MacVector Version 10.1 (MacVector Inc, Cambridge, UK)  
 
2.1.4 Chemicals 
Acetic acid       
Aceton    
Acrylamid-solution (30%) Mi 
37,5:1  
Annexin V conjugates 
Agar      
Agarose  
Argyrin F    
Ammoniumacetat   
Ammoniumsulfat  
Baker, Griesheim 
Merck, Darmstadt 
AppliChem, Darmstadt 
 
AppliChem, Darmstadt 
Bioline, Luckenwalde 
Bioline, Luckenwalde  
Leibniz Universität Hannover 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
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Ampicillin 
Antigen unmasking solution 
Antifoam     
BactoTM peptone   
Benzamidine 
ß-Glycerophosphat      
ß-Mercaptoethanol    
Bromophenol bleu   
Boric acid    
Calcium chlorid    
Cesium chloride 99% 
DAB substrate Kit                                                                                                                                                                                                                  
DEPC 
dNTP 
EDTA 
EGTA 
Ethanol 
Ethanolamine    
Ethidiumbromide   
FCS 
Formaldehyde solution min. 
37% free from acid   
Gelatine     
Glucose                                                                        
GlutaMax                                                                      
Glycine   
G-sepharose beads   
Guanidine thiocyanate                                                     
Vector, Eching 
Sigma-Aldrich, Schnelldorf 
Becton Dickinson, Heidelberg 
Sigma-Aldrich, Schnelldorf 
Roche, Mannheim 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Merck, Darmstadt 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Vector, Eching 
AppliChem, Darmstadt 
Fermentas,  St. Leon-Rot 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Meck, Darmstadt 
Sigma-Aldrich, Schnelldorf 
AppliChem, Darmstadt 
Biochrom, Berlin 
Merck, Darmstadt 
 
Sigma-Aldrich, Schnelldorf 
AppliChem, Darmstadt 
Invitrogen, Karlsruhe 
AppliChem, Darmstadt 
GE Healthcare, München 
Sigma-Aldrich, Schnelldorf 
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HEPS      
30% H2O2 
Hot start DNA Polymerase  
Imidazole         
Isopropanol                                                                     
Kanamycinesulfate     
Lauroylsarcosine                                                       
Luminol min 97%, HPLC      
Magnesium chloride                                                         
Methanol    
MG132 
Mounting Medium 
MTT assay WST-1 
Natrium  
Natriumchlorid  
Noble Agar                                                                  
Nonfat dried milk powder 
Nonidet P40 
Normal Horse Serum 
p- Cumaric acid  
Penicillin-Streptomycin solution                                                                 
Phenol        
Polyethylenimine   
Ponceau S solution                                                                     
Potassium acetate                 
Potassium chlorid                                                             
Potassium dihydrogen 
phosphate                                    
AppliChem, Darmstadt 
Sigma-Aldrich, Schnelldorf 
Qiagen, Hilden 
AppliChem, Darmstadt 
Merck, Darmstadt
AppliChem, Darmstadt 
Sigma-Aldrich, Schnelldorf
Sigma-Aldrich, Schnelldorf 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Sigma-Aldrich, Schnelldorf   
Vector, Eching 
Roche, Mannheim 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
BD Difico, Heidelberg 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Vector, Eching 
Merck-Schuchard, Darmstadt 
Invitrogen, Karlsruhe 
AppliChem, Darmstadt 
PfuTurbo DNA polymerase  
Roth, Karlsruhe
Sigma-Aldrich, Schnelldorf   
AppliChem, Darmstadt
AppliChem, Darmstadt 
AppliChem, Darmstadt 
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Prolong® gold antifade reagent                                      
Propidium iodid        
Proteinase K 
Restriction enzymes                                                                                                                                                   
SDS                                                                                                                                                                    
Sodium carbonate                                                            
Sodium chloride                                                                
Sodiumdihydrogenphosphat                                            
Sodium floride                                                                                                                           
Sodium pyrophosphate                                                    
Talon metal affinity resins                                                
TEMED                                                                             
Thymidine 99-100%    
Thermo Pol buffer          
Tris                                                                                    
Triton X 100                                                                      
Trypsin/EDTA solution   
Trypton 
Tunicamycin 
Tween-20                                                                          
Urea 
Vectastain Elite 
ABC-Peroxidase Kits                                                                                                                                                           
X-Gal for microbiology BC                                                                 
Xylenecyanol  
Merck, Darmstadt 
Invitrogen, Karlsruhe 
Fluka, Steinheim    
AppliChem, Darmstadt 
NEB, Fermentas 
AppliChem, Darmstadt    
AppliChem, Darmstadt     
AppliChem, Darmstadt  
AppliChem, Darmstadt
AppliChem, Darmstadt                                                                                                                                                                                                                                                                                                                                                                                      
Sigma-Aldrich, Schnelldorf 
Becton Dickinson, Heidelberg 
AppliChem, Darmstadt 
Sigma-Aldrich, Schnelldorf 
Biolabs, Frankfurt
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Biochrom, Berlin 
AppliChem, Darmstadt 
Sigma-Aldrich, Schnelldorf 
AppliChem, Darmstadt 
AppliChem, Darmstadt  
Vector, Eching 
Peqlab, Erlangen 
AppliChem, Darmstadt  
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2.1.5 Buffers and solutions 
2.1.5.1 Buffers for the cell culture 
Dialysis buffer  pH 7,4       
HEPS 
NaCl 
10 mM 
150 mM 
 
10X PBS 
NaCl 
KCL 
Na2HPO4 
KH2PO4 
137 mM 
2,7 mM 
100 mM 
2 mM 
The pH was adjusted to 7,4. PBS was sterilised by autoclaving.  
 
Annexin-binding buffer pH 7,4 
HEPS  
NaCl 
CaCl2 
10 mM 
140 mM 
2,5 mM 
 
Proteinase K buffer 
Tris pH 8,5 
EDTA  
SDS  
NaCL 
ddH2O 
  100 mM 
  5 mM     
  0,2 % 
  200 mM 
  100 ml 
 
2.1.5.2 Buffers and solutions for protein extraction and analysis 
2.1.5.2.1 Protein extraction 
RIPA 
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Tris pH 8,0 
NaCL 
NaF 
Na4P2O7 
EDTA 
EGTA 
NP-40 
DOC 
SDS 
 50 mM  
 80 mM  
 50 mM  
 20 mM  
 1 mM  
 1 mM  
 1 %  
 1 %  
 0,1 %  
 
NP40 
Tris pH 7,5 
NaCl 
NaF 
Na4P2O7 
EDTA 
ß Glycerolphosphat 
NP-40 
50 mM 
150 mM 
50 mM 
20 mM 
1 mM 
10 mM 
0, 5 % 
 
4XSB 
Tris pH 6,8        
SDS  
Glycerol   
ß-Mercaptoethanol      
Bromophenol blue   
0,25 M     
8 %  
40 %  
10 %  
0,05 %  
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Protease and phosphatase inhibitors (for 10 ml buffer) 
 Inhibitor of Final concentration 
Vanadat 
Leupeptin 
Leupeptin 
Benzamidin 
Aprotonin 
PMSF 
Tyrosin-phosphatase 
Aspartic-protease 
Serin-cystein protease 
Trypsin, thrombin, Plasmin 
Trypsin, chymotrypsin, Kallikerin 
Serin-protease 
   
  100 uM 
   
  0,5 ng/ml 
  2,5 ng/ml 
  0,15 mM 
  0,5 % 
  0,5 mM 
Table 1: List of the used protease and phosphatase inhibitors 
 
2.1.5.2.2- Protein analysis  
Separating Gel 
% Acrylamid 7,5 % 10 % 12 % 14 % 15 % 
Acrylamid 2,5 ml 4,1 ml 3,4 ml 2,7 ml 2,45 ml 
Tris pH 8,0 2,5 ml 2,5 ml 2,5 ml 2,5 ml 2,5 ml 
H2O 4,85 ml 4,1 ml 3,4 ml 2,7 ml 2,45 ml 
10 % SDS 100 ul 100 ul 100 ul 100 ul 100 ul 
TEMED 15 ul 15 ul 15 ul 15 ul 15 ul 
10 % APS 105 ul 105 ul 105 ul 105 ul 105 ul 
Table 2: Recipes of the used separating gels 
Stacking gel 
Acrylamid 
Tris 6,8 pH 
ddH2O  
1,13 ml 
1,75 ml 
3,2 ml 
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10 % SDS 
TEMED 
10 % APS 
70 ul 
7 ul 
70 ul 
Table 3: Recipe of the used stacking gel 
 
SDS running buffer (10x) 
Tris pH 8,3  
SDS   
Glycine              
250 mM 
    1 % 
1,92 M 
 
Western transfer buffer (10x) 
Tris 
Glycine               
 
250 mM   
1,92 M     
 
TNT western blot washing buffer (10x) 
NaCL 
Tris pH 7,5     
Tween-20  
 
  1,5 M 
  100 mM 
  0,5 % 
 
Blocking solution     
Milk powder, nonfat 5 % in TNT 
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ECL solution 
Solution 1 
Luminol  
p-cumaric acid  
Tris pH 8,5  
 
250 mM  
0,4 mM  
0,1 M 
 
Solution 2 
Tris pH 8,5  
30 % H2O2 
 
0,1 M 
0,061 % 
2.1.6 Antibodies 
2.1.6.1 Antibody for Western blot 
Primary antibody  
Target 
Working 
dilution 
Source Manufacturer 
Anti-E-Cadherin Rabbit mAb  1:1000 rabbit Cell signaling 
Anti-N-cadherin rabbit monoclonal  1:50000 rabbit 
 
Millipore 
 
Polyclonal anti-P21 (C-19) 1:500 rabbit Santa cruz 
Polyclonal anti-P27 (C-19) 1:500 rabiit Santa cruz 
Monoclonal anti-Actin (C-2) 1:10000 mouse Santa cruz 
 
Table 4: List of primary antibodies used for western blo 
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Secondary antibodies 
Target Working 
dilution 
Manufacturer 
Anti-mouse IgG peroxidase 
conjugated 
1:10000 Amersham, 1,5 mg/ml 
Anti-rabbit IgG peroxidase conjugated 
Mouse TrueBlotTM  HRP-conjugated 
anti-mouse IgG ( clone eB144/7A7) 
1:10000 
1:15000 
Amersham, 1,5 mg/ml 
Bioscience 
Table 5: List of secondary antibodies used for western blot 
 
2.1.6.2 Solutions and antibodies for immunohistochemistry 
 
Antigen Unmasking Solution 
Antigen unmasking solution          1:100 diluted in dH2O  
 
Blocking Solution (in PBS) 
Normal Horse serum                5% 
Trinton X-100                      0.3% 
 
Acid Rinse Solution 
Glacial Acetic acid                  2% 
 
Ethonal  
100%, 95%, 70%, 40% 
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Primary antibody 
Target 
Working 
dilution 
Source Manufacturer 
Ki-67   1:200 mouse Novocastra 
Anti-CD34 antibody 1:200 mouse Novus 
Table 6: List of primary antibodies used for IHC 
 
2.1.6.3 Primers and PCR program for Genotyping 
2.1.6.3.1 Primers 
 
 
Table 7: List of used primers for genotyping 
 
2.1.6.3.2 PCR program 
p53lox/+ 
15,87 μl MilliQ 
2 μl 10x ThermoPol Reaction Buffer 
0,13 25mM MgCl2  
0,5 μl Primer p53 Forward 
p53   forward 
      backward 
AGCACATAGGAGGCAGAGAC 
Sigma-Aldrich 
CACAAAAACAGGTTAAACCCAG 
5`-Kozak-3`LoxP1 CTAGCCACCATGGCTTGAGT 
3`-Flank-5` LoxP1 TCCGAATTCAGTGACTACAGATG 
Gabra 12 CAATGGTAGGCTCACTCTGGGAGATGATA 
Gabra 70 AACACACACTGGCAGGACTGGCTAGG 
Pdx1-Cre 26 CCTGGAAAATGCTTCTGTCCG 
Pdx1-Cre 36 CAGGGTGTTATAAGCAATCCC 
 
p
5
3
 w
t 
 
p
5
3
 w
t 
 
p
5
3
 L
/+
 
 
p
5
3
 L
/L
 
 
p
5
3
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/L
 
p53
lox/+
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0,5 μl Primer p53 Backward  
0,4 μl dNTP’s 
0,1 μl Qiagen Hot star Taq polymerase 
19,5 μl reaction 
+ 0,5 μl DNA  
20 μl  
 
LSL-KrasG12D 
15,5 μl MilliQ water 
2 μl 10x ThermoPol Reaction Buffer 
0,15 25mM MgCl2  
0,34 μl 20μM Gabra 70 
0,34 μl 20μM Gabra 12 
0,34 μl 20μM 5`-Kozak-3`LoxP1 
0,34 μl 20μM 3`-Flank-5`LoxP1 
0,4 μl dNTP’s 
0,1 μl Qiagen Hot star Taq polymerase 
19,5 μl reaction 
+ 0,5 μl DNA  
20 μl  
---350bp=presence(KrasG12D +) and absence(KrasG12D -) 
  bottom band=300bp is internal control (Gabra) 
 
Pdx1-Cre 
23,5 μl MilliQ water 
3μl 10x Qiagen Reaction Buffer 
0,2 μl 25mM MgCl2  
0,5 μl 10μM Gabra 70 
Pdx1- Cre 
C
re
 +
v
e
 
C
re
 -
v
e
 
C
re
 +
v
e
 
C
re
 -
v
e
 
LSL-Kras
G12D
 
K
ra
s
 -
v
e
 
K
ra
s
 +
v
e
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0,5 μl 10μM Gabra 20 
0,5 μl 10μM Cre 36 
0,5 μl 10μM Cre 26 
0,6 μl dNTP’s 
0,2 μl Qiagen Hot star Taq polymerase 
29,5 μl reaction 
+ 0,5 μl DNA  
30 μl  
 
---Band 400bp = presence(Pdx1-Cre +) and absence(Pdx1-Cre -) 
  Bottom band 300bp = internal control (Gabra) 
 
Standard program: 
 
    Lid on 110°C 
 
    95°C    15'         DNA Denaturing 
     
    94 °C    30''     DNA Denaturing 
    60 °C    30''-1`    Primer Annealing    30 - 33x 
    72 °C    50''-1`     Strand Elongation 
     
              72 °C    6'     Final Elongation 
 
              10 °C                Hold 
The PCR product can be analysed using agarose gel electrophoresis. 
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2.2 Methods 
2.2.1 Cells Culture 
2.2.1.1 Cell lines and culture medium 
All operations were performed in a laminar flow hood under aseptic conditions. 
The work area was always cleaned with 70% ethanol, and sterile cell culture 
dishes and sterilized glass pipette were used. Cells were regularly tested on 
mycoplasma contamination. Two human PDAC cell lines: Panc-1 (cultured 
from a primary tumor without evidence of metastasis) and KP3 (cultured from 
liver metastases of a human pancreatic tumor) were used in this experiment. 
Cells were provided by Nabeel Bardeesy (MGH Cancer Center, Boston, USA). 
These two cell lines were originally obtained from the MGH Center for 
Molecular Therapeutics (CMT). The cell lines were maintained at 37°C under a 
5% CO2 environment in RPMI 1640+Glutamax (Invitrogen, Karlsruhe, 
Germany) enriched with 10% fetal calf serum (FCS) (Biochrom, Berlin, 
Germany) and antibiotics of penicillin / streptomycin (100 units/ml) (Invitrogen, 
Karlsruhe, Germany). After 2-3 days, the cells were passaged. 
 
2.2.1.2 Subculturing adherent cell lines 
Adherent cells were subcultured after reaching 70-90 % confluency. Culture 
medium was removed from the plate, and cells were washed 2 times with 
PBS. To detach adherent cells, the plate was incubated with 1 ml trypsin at 37
°C for 1-2 min. The incubation time might differ from cell line to cell line. . The 
detached cells can be examined under the microscope and the proteolytic 
reaction can be quickly terminated by the addition of pre-warmed growth 
medium. Cells were re-suspended with the appropriate volume of medium and 
1x106 cells were split into fresh 10cm2 plates containing complete medium. 
Alternatively, cells can be counted using a hemocytometer and diluted to 
desired density. 
 35 
 
2.2.1.3 Quantification of cell number and viability with hemocytometer and 
trypan blue staining 
To perform accurate quantification and to standardise culture conditions, it is 
necessary to determine the cell number. The hemocytometer was the 
instrument used in this work to determine the cell number. 
The hemocytometer consists of 4 corner squares, which are divided into 16 
tertiary squares. Cells in the four corner squares were counted, and the 
number of cells per ml was determined according to the following equation: 
Cells/ml= average count per square x dilution factor x104 
(Each square is 1m2 and the depth is 0,1 mm) 
The number of total cells was counted as follows: 
Total cells= cells/ml x the volume of cell suspension from which sample were 
taken. 
 
2.2.1.4 Preservation of cell lines 
2.2.1.4.1 Freezing 
For long-term storage cells have to be frozen. FCS was used in combination 
with 10 % DMSO to store cells at -80°C or lower. The use of DMSO as 
cryoprotective agent is required to preserve cells, to reduce the freezing point 
and to allow a slower cooling rate. Gradual freezing is necessary to reduce the 
risk of ice crystal formation and cell damage. For Freezing, after trypsinisation 
and centrifugation for 5 min at 800 rpm, the pellet was resuspended in freezing 
medium to obtain 1x106 cells/ml. 1ml aliquots of suspension cells was pipetted 
into labeled freezing tubes. Covering the tubes with towels allows a slower 
freezing at -80°C. 
 
2.2.1.5.2 Thawing 
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Cells were removed from frozen storage and quickly thawed in a 37°C water 
bath. After thawing, the cell suspension was placed into a 10cm2 plate 
containing 8 ml warm medium. The medium was changed in the next day to 
remove all traces of DMSO. 
2.2.2 Drug preparation and in vitro treatment  
2.2.2.1 Agyrin F 
AF was supplied by Biomolecular drug center (BMWZ), Leibniz University of 
Hannover. AF was prepared as a 5mg/ml stock in dimethylsulfoxide, DMSO 
(AppliChem, Darmstadt, Germany) in the Intern medicine I lab, University clinic 
of Tübingen. Then we make the aliquots of the drug by 0.5mg/ml and keep in 
-20℃.  
 
2.2.2.2 In vitro Treatment  
Cells were treated with DMSO or AF in different concentrations (0.5ug/ml, 
2ug/ml, 6ug/ml) and were analyzed after 24hrs, 48hrs and 96hrs for certain 
experiment. 
 
2.2.3 Determination of cell number and proliferation using WST-1 assay 
The cell viability was examined by the WST-1 assay (Roche Diagnostics, 
Mannheim, Germany). Living cells with a functional mitochondrial 
dehydrogenase will split the red WST-1 (watersoluble tetrazolium) 
enzymatically. In doing so, it will produce the orange formazan. A total 5x10
3
 
cells with 200 µl complete medium were seeded per well into several sterile 
96-well tissue culture plates and PBS was pipetted into the surrounding wells in 
order to keep the medium from drying. The plates were incubated over night. 
After 24h incubation in the incubator, one 96 wells cell culture plate was 
selected as the zero-hour value. In each chamber we put 10 µl WST-1 reagent 
and after an incubation period of 2 hrs in incubator, The plate were read at a 
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wavelength of 492 nm with reference wavelength of 650 nm using a Micro 
plate-Reader Multiskan Plus (Titertek-Berthold, Pforzheim, Germany). 
Following the treatment with AF in different concentration (0.5ug/ml, 2ug/ml, 
6ug/ml) and DMSO control, cells of the remaining plate were further incubated 
for additional time points (24, 48, 72 and 96 hrs). Every day, cell growth was 
examined microscopically. Then 10 µl of WST-1 reagent was added per well 
daily and repeat the same step as zero-hour-value. The averages of 
proliferations index were obtained during the evaluation on 100% of the 
untreated control on day zero.  
 
2.2.4 Apoptosis Assays 
2.2.4.1 Annexin V + Propidium iodide (PI) apoptosis assay 
Apoptosis is the process of programmed cell death (PDS) that may occur 
in multicellular organisms. The change in the double lipid membrane structure 
is one of the earliest. In this process, it comes to the translocation of the 
Membranphospholipids phosphatidylserine (PS) from the inner to the outer 
membrane, where the membrane remains intact. Annexin V is a protein which 
has a high binding capacity for PS and thus binds to apoptotic cells. Annexin V 
may be conjugated to fluorochromes such as FITC and detected by flow 
cytometry. Since Annexin V but can also bind to PS necrotic cells, 
simultaneous labeling with PI is carried out, which can pass only in the event of 
a damaged cell membrane (necrotic or dead cells) in the cell and intercalated 
in the DNA. Living cells are thus Annexin V and PI negative. Early apoptotic 
cells are Annexin V positive and PI negative. Late apoptotic cells or dead cells 
are both Annexin V and PI positive. The quantitative measurement of the 
percentage of apoptotic cells will be performed in the whole population 
(according to manufacturer information). 
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2.2.4.2 Experimental Procedure 
Cells were seeded in 6-well tissue culture plates at a density of 1x10
5 
cells per 
well and were incubated over night at 37
o
C. These cells were further treated 
with AF as described in proliferation assay. The medium was changed every 
two days. At 48 and 96 hrs, the cells were harvested. For this purpose, firstly, 
the spent medium was aspirated and transferred in each case in the 
corresponding test tube. The cell layer was washed with 1×PBS and incubated 
after addition of 0.5 ml trypsin-EDTA to each well for 60 seconds in an 
incubator. After the proteolytic, remove of the cells from the medium into the 
test tubes in the corresponding cavity was transferred back to stop the trypsin 
activity. Then centrifuge for 5 min at 1000 rpm. The supernatant was 
discarded, the cell pellet was resuspended with 1 ml 1×PBS and centrifuged 
for another 5 min. The supernatant was discarded again, the cell pellet was 
suspended with 1ml 1xBinding Buffer (FITC Annexin V Apoptosis Detection Kit 
I, BD Biosciences) on ice. The untreated control was divided into three tubes 
(Annexin V-control, PI-control and unlabeled control). 5μl Annexin V and 10μl 
PI (Annexin V FITC Apoptosis Detection Kit I, BD Biosciences) were added 
into their corresponding tubes. After a fifteen-twenty-minute incubation on ice 
in dark, the prepared sample should be detected on the flow cytometer within 
one hour. The signal was detected using FACS calibur flow cytometer (BD, 
Heidelberg, Germany) and analyzed using FlowJo Version 7.6 software (Tree 
Star Inc., Ashland, USA). The unmarked population was served as the basal 
rate of apoptotic cells. The coordinate field has been divided by a cross so that 
the rate of apoptotic and dead cells of the unlabeled control corresponded to 
approximately zero. Characterized the proportion of apoptotic cells in the 
untreated cell population of the other populations of apoptotic cells was 
subtracted to obtain the respective proportion of the cells, the committed by a 
particular treatment induced apoptosis. Each cell population was evaluated on 
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the basis of the created template coordinates and adds the values for the early 
apoptosis in connection. 
 
2.2.5 Migration analysis with Wound-healing assay 
2.2.5.1 Mirgration process  
Cell migration is a complex process, both at the physiological wound healing, 
as well as in tumor formation in which metastasis plays an important role. A 
Wound-Healing assay mimics the directional cell migration, which takes place 
during wound healing. Thus it can be examined if the treatment with AF in 
comparison with the control has an inhibitory effect on the migration of the 
PDAC cells. 
 
2.2.5.2 Experimental Procedure 
Cell lines were seeded in a 6-well plate and left to reach 80% confluence. 
Initially, cells were starved for 24h in media containing 2% FCS.  Then KP3 
and Panc-1 cell lines were further incubated for 48hrs in the starvation media 
containing either the controls (DMSO) or AF. Afterwards a scratch was done 
using a 10µl white tip for each treatment.  Then cells were washed with PBS 
and photographed using Leica DMI 6000 B microscope (Leica, Wetzlar, 
Germany). Cells were incubated for an additional 24h after which the 
photographs were taken for the wounded area. The migrating cells were 
calculated according to the following formula:  
 
 
 
The width of the respective wound determined (there were 3 per measurement 
points per wound selected). For each treatment, the difference in wound 
diameter between time 0h and time 24hrs was determined and related to the 
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time 0h. Since each wound has several measuring points, an average was 
determined and the migration index. 
 
2.2.6 Invasion measurement with BD Matrigel ™ Invasion Chamber 
BioCoat ™ 
2.2.6.1 BD Matrigel Invasion Chamber BioCoat 
The membrane of the invasion chamber has 8µm large pores, which is 
covered by a thin Matrigel Basement membrane matrix. This is located 
between the FCS-free and the complete medium and serves as an artificial 
basement membrane which covers the pores, so that non-invasive cells are 
prevented from migrating through the pores. Invasive cells, attracted by the 
complete medium, however, can become detached from the membrane and 
invade through the pores. 
 
2.2.6.2 Experimental Procedure 
The invasion chamber (stored at -20°C) was warmed at RT and rehydrated 
after reaching RT with serum-free medium for 2 hrs in the incubator. 
Subsequently, the medium was aspirated and administered 2.5 ml complete 
medium in the environmental chamber. A total of 2.5x10
5 
cells / 2ml were 
plated in the upper chamber filter in serum free media. The cells were treated 
simultaneously with AF (0.5μg/ml, 2μg/ml, 6μg/ml) and control (DMSO). The 
invasion assay utilized 6-well BD BioCoat™ Matrigel™ Invasion Chamber (BD 
Biosciences, Bedford, UK). These upper chamber filters were placed into the 
BD Falcon TC Companion Plate (BD Biosciences, Bedford, UK) containing 
10% FCS. After 48 hrs incubation at 37°C, 5% CO2 atmosphere the cells on 
the upper surface of the membrane were mechanically removed with cotton 
swab. The invading cells were fixed in 100% ice-cold methanol (AppliChem, 
Darmstadt) and stained with 1% toluidine blue (Sigma-Aldrich, St. Louis, USA) 
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in 1% borax (Sigma-Aldrich, St. Louis, USA). Cells were then counted under 
the microscope (Leica DM 5000 B, Wetzlar, Germany). The calculation of the 
invading cells was done according to the BD protocol. With a light microscope 
respectively cells were counted in 5 fields of view and made photos (40x 
magnification). The respective mean values were based on the average of the 
DMSO control and calculated as the invasion index. 
 
 
 
 
2.2.7 Soft Agar Assay 
2.2.7.1 Soft agar colony formation 
The soft agar colony formation assay is a technique widely used to evaluate 
cellular transformation in vitro. In this technique, cells were dispersed onto a 
culture plate and grown in the presence of 'feeder' cells or conditioned medium 
to provide necessary growth factors. In the traditional soft agar colony 
formation assay, cells are grown in a layer of soft agar mixed with cell culture 
medium that rests on another layer of soft agar, also mixed with cell culture 
medium, but containing a higher concentration of agar. This prevents cells 
from adhering to the culture plate, yet allows transformed cells to form visible 
colonies. The rationale behind this technique is that normal cells depend on 
cell to extracellular matrix contact to be able to grow and divide. Conversely, 
transformed cells have the ability to grow and divide irrespective of their 
surrounding environment. Therefore, cells able to form colonies in an 
anchorage-independent manner were considered to be transformed and 
carcinogenic. 
 
2.2.7.2 Experiment Procedure 
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Before experiment, maintain the waterbath at 45°C. Make 50 ml of 5% Noble 
agar (Difco; BD Biosciences, Franklin Lakes, NJ) in water, autoclave to 
dissolve. When agar is melted, mix agar on stir plate, leave cool for 15 mins. 
To 120 ml of medium, add 30 ml of 5% agar, you will get 1% agar in the end. 
Soft agar plates were prepared in 6-well plates with bottom layer of 1% nobel 
agar  in complete culture medium. 6 x104 cells/well were suspended in 3mL of 
0.5% of agarose along with the different concentration of drug (AF) and control 
(DMSO) and were seeded as a top layer on to 1% agar coated plates. The 
cells were incubated for 2 weeks at 37°C in a humidified atmosphere 
containing 5% CO2 and counterstained with p-iodonitotetrazonium violet 
(Sigma Aldrich, Germany). The number and size of colonies were determined 
after 3 weeks under the microscope.  
 
2.2.8 Protein extraction and western blotting 
Certain proteins in cell lysates can be detected using Western blotting. 
Proteins are separated by electrophoresis according to their molecular weight 
when transferred to a membrane. By means of specific antibodies the target 
protein can then be detected on the membrane. The peroxidase coupled to the 
secondary antibody converts the substrate luminol, chemiluminescent signals 
can be displayed on an X-ray film (according to manufacturer information). 
 
2.2.8.1 Cell Culture 
Panc-1 and KP3 cells treated with DMSO and AF (24hrs, 48hrs and 96hrs) 
were collected and transferred to 15ml test tubes and centrifuged for 5 min at 
1000rpm. The supernatant was discarded, the cell pellet was resuspended 
with 1ml ice cold 1×PBS and centrifuged again. The supernatant was 
discarded and the cell pellets were incubated in 200μl Western lysis buffer 
buffer supplemented by protease and phosphatase inhibitors for 30mins on 
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ice. In addition, sonification was made the on ice then the sonification was 
made the on ice (twice each 15 seconds per cell pellet) for the destruction of 
the intact cell walls. Thereafter, the suspensions were centrifuged for 25 min at 
13000Rpm and 4°C. The supernatant containing the cell lysate was carefully 
transferred into Eppendorf tubes and determined the protein content. 
 
2.2.8.2 Determination of protein concentration 
The protein determination was carried out according to manufacturer's 
instructions with the DC Protein Assay (BioRad). The proteins react with the 
alkaline copper tartrate solution and Folin reagent, this leads to a color 
change. The absorbance (650nm) was measured with the Micro plate-Reader 
Multiskan Plus (Titertek-Berthold, Pforzheim, Germany). The mean value of 
the protein sample from the tripltcate well was used for analysis. The amount 
of cell lysate in 1μl calculated as follows: 100 / ((x-0.0627) / 0,136). It was filled 
with western lysis buffer to 100 μl by adding 25μl 4x protein loading buffer. 
 
2.2.8.3 Preperation of separating and stacking SDS polyacrylamide gels 
The separating gel was poured between two glasses plates sealed with 100% 
ethanol. After 30 mins, the ethanol was removed. The stacking gel was poured 
on top of the separating gel.  
 
2.2.8.4 Electrophoresis 
The gel was placed into the electrophoresis chamber and filled with 1×SDS 
running buffer. Before the samples were loaded, they were boiled for 5 min at 
95 °C and then centrifuged. As protein markers page ruler plus prestained 
protein ladder (Fermentas) was used. Electrophoretic separation was 
conducted at 80V until the separating gel was reached, then the voltage was 
increased to 120V.  
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2.2.8.5 Protein transfer to PVDF membrane 
The PVDF membrane was briefly incubated in 100% methanol, and then put in 
1x western transfer buffer. When assembling the Blotting-sandwiches (holder / 
sponge / Watman filter paper / gel / PVDF membrane / Watman filter paper / 
sponge / holder) bubbles were pushed away thoroughly. The protein transfer 
was performed at 4 ° C, 0,35mA and 100V for one hour. Subsequently, the 
PVDF membrane was shifted to blocking solution (5% dried milk AppliChem, 
Darmstadt, Germany) for one hour and then washed with 1xTNT Buffer on the 
shaker. 
 
2.2.8.6 Antibody incubation and development 
After washing, the memberanes were probed with primary antibodies against 
E-cadherin (1:1000; Cell signaling, 24E10), N-cadherin (1:50,000; Millipore, 
EPR1792Y), Actin (2:10.000; Sigma, AC-74), p27kip1 (1:500; Santa Cruz 
Biotechnology, C-19), p21waf1/cip1 (1:500; Santa Cruz Biotechnology, sc-6246) 
overnight. The next day membrane was washed three times for 10 min with 
1xTNT washbuffer and then incubated for 1 hour at RT with the secondary 
antibody. After another three washes with 1xTNT wash buffer the PVDF 
membrane were exposed to Amersham Hyperfilm ECL (GE Healthcare 
Limited Buckinghamshire, UK), ECL-films were placed on the membrane and 
this developed after an exposure time of 1-5 min in the dark. 
 
2.2.9 Cell Senesence assay 
2.2.9.1 X-gal 
Senescence-associated β-galactosidase activity is a widely used biomarker for 
assessing replicative senescence in mammalian cells. This enzymatic activity 
has generally been measured by staining cells with the chromogenic substrate 
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5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-gal) at pH 6.0, a reaction 
condition that suppresses lysosomal β-galactosidase activity sufficiently to 
ensure that most nonsenescent cells will appear unstained. 
2.2.9.2 Experiment Procedure 
To determine the senescence, cells were seeded (2×104 /ml) in six well plate 
and were further treated under the same conditions described for WST-1 
assay. After the respective treatment  cells were fixed with 0.5% 
glutaraldehyde solution (in PBS, pH 7.4) for 5min at RT. Followed by washing 
with PBS once and twice with PBS/Mgcl2 (pH 5.5) for 5 min at RT. Freshly 
prepared X-gal solution containing PBS/Mgcl2, 0.2M K3Fe[8]6, 0.2M K4Fe[8]6,  
X-Gal  stock (40x) (Peqlab; 37-2610) was added to the cells. The cells were 
incubated at 37o C for few hrs sealed and protected from light. After staining 
the cells for desired intensity, the cells were washed three times with PBS for 5 
min. Post fixed with 4% Formalin in PBS for 30 min at RT followed by washing 
for three times with PBS at RT RT. Pictures were taken and the stained cells 
were counted under the microscope (Leica DM 5000B, Leica Wetzlar). The 
percentage of positive cells (of the total cell number) in the treated sample was 
determined and plotted. 
  
2.2.10 Cell Cycle 
2.2.10.1 Cell-cycle analysis using propidium iodide staining and flow cytometry 
Cell cycle analysis is a method in cell biology that employs flow cytometry to 
distinguish cells in different phases of the cell cycle. Before analysis, the cells 
are permealised and treated with a fluorescent dye that 
stains DNA quantitatively, usually PI. The fluorescence intensity of the stained 
cells at certain wavelengths will therefore correlate with the amount of DNA 
they contain. As the DNA content of cells duplicates during the S phase of the 
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cell cycle, the relative amount of cells in the G0 phase and G1 phase (before S 
phase), in the S phase, and in the G2 phase and M phase (after S phase) can 
be determined, as the fluorescence of cells in the G2/M phase will be twice as 
high as that of cells in the G0/G1 phase. Cells with fractional DNA contents, a 
situation occurring during apoptosis, can be identified as a “sub-G1” 
population, the presence of a sub-G1 peak in the fluorescent signal is often 
interpreted as a loss of DNA due to its fragmentation associated with 
apoptosis. Cell-cycle anomalies can be symptoms for various kinds of cell 
damage, for example DNA damage, which cause the cell to interrupt the cell 
cycle at certain checkpoints to prevent transformation into a cancer cell 
(carcinogenesis). Other possible reasons for anomalies include lack of 
nutrients, for example after serum deprivation. 
 
2.2.10.2 Experiment Procedure 
2x105 Panc-1 and KP3 cells were treated cultured with AF treatment (48hrs 
and 96hrs). First wash with 1xPBS and trypsinized them resuspended in 
medium + 10% FCS, centrifuged (1000 rpm, 5 mins). Pellet were resuspended 
in 1ml 1xPBS and centrifuge again. Then Pipet cells were fixed in suspension 
into 3 ml absolute 80% Ethonal overnight at -20°C, keep vortexing in order to 
prevent clustering of cells during the fixation. Incubate on ice for 15 min (or 
over night at -20°C).The next day pellet the cells at 1500 rpm for 5 mins. 
Suspend the pellet in 500 µl PI-solutionin-PBS: 50 µg/ml PI from 50x stock 
solution (2.5 mg/ml) 0.1mg/ml RNase A and Incubate for 40 min at room 
temperature following flow cytometry analysis. 
 
2.2.11 Animals and treatment 
2.2.11.1 Animals and genotyping analysis 
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Therapeutic studies in vivo were performed with Pdx1- Cre; LSL-KrasG12D; p53 
lox/+ mice (KPC Mouse model) which have been previously described [53]. The 
transgenic Pdx1-Cre mice and p53 lox/+ mice were obtained from Aram Hezel 
(University of Rochester Medical Center, USA). Kras mice were kindly 
provided by Lars Zender (UKT, Germany). The mice were crossed and 
genotyped to obtain the mice with background Pdx1-Cre; LSL-KrasG12D; p53 
lox/+ (according to 2.1.6.3). 
 
2.2.11.2 Drug and treatment in vivo 
A total of 18 mice were used for the in vivo experiment. We initiated an animal 
trial with 6 mice per treatment group. Mice were treated intraperitoneally with 
AF (1mg/kg/body weight, Day1-Day3), a combination of AF (1mg/kg/body 
weight Day1-Day3) + Gemcitabine (100mg/kg/body weight Day 5) or 
vehicle(PBS) starting at an age of 14-weeks (Figure.5). The mice were 
sacrificed when critical illness was developed; sizes of pancreas and visible 
tumor were measured by caliper and organ tissues were harvested. Tumor 
volume was calculated using the following formula: Tumor volume V= [(ð\6) x 
(Length) x (Width
2
)]. The tumor tissues were snap frozen for protein analysis 
and fixed in 4% formalin for histology. The other organs were collected for 
further histological analysis. All animals were analyzed for metastases and 
ascites. 
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Figure.5 Design for survival experiment 
 
2.2.12 Immunohistochemistry  
2.2.12.1 The principle of immunohistochemistry 
Immunohistochemical staining allows antigens in tissue sections being 
demonstrated. In the indirect method, a specific primary antibody binds to the 
antigen and in doing so it can bind a secondary antibody. The visualization of 
these bindings is done by the Avidin-Biotin-Complex (ABC) method: Avidin 
binds biotin with the coupled secondary antibody. The colorless 3'3 
'diaminobenzidine (DAB) is activated by binding to the biotin-avidin-peroxidase 
complex and assumes a brown color, so ultimate the antigen is visible. 
 
2.2.12.2 Experimental Procedure 
Tissue sections were fixed in 4% formalin (Sigma-Aldrich, St. Louis, USA) 
overnight, stored in PBS and embedded in paraffin. But they were incubated 
overnight in the hybridization oven at 55 ° C before experiment. The remaining 
paraffin was removed by the incubation in xylene. Thereafter, the sections 
were rehydrated with graded concentrated alcohol (6 min to 100%, 95%, 75%, 
40% ethanol) and then rinsed three times for 3-5 min with 1xPBS. Because 
KPC Mouse 
(Pdx1- Cre; LSL-Kras
G12D
; p53 
lox/+
)  
14 weeks 
Survival  
Vehicle (PBS) 
AF+G 
Day 1-Day3 AF 1mg/kg/day 
Day 5 G 100mg/kg 
AF  
Day 1-Day 3 1mg/kg/day  
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some proteins are cross-linked by the formalin fixation, they can not be 
detected. In order to establish their spatial structure again, the vapor pressure 
method was used. But the slides were put in a pressure cooker filling with 
antigen Unmasking Solution (Vector Laboratories) / autoclaved water (1: 100 
dilution) dipped. After the water has been brought to a boil, was 15 to 20 min 
waiting, only to reduce the pressure by running cold water and gently remove 
the sections. Then they were rinsed three times for 3-5 min and then put into 
1% hydrogen peroxide / water for 10 min. The sections were washed again 
three times for 3 min each in 1×PBS, and then overlap 100 µl blocking solution 
(5% normal serum + 0.3% Triton X-100, Vector Laboratories, Inc., 
Burlingame), cover with parafilm and incubate for one hour in a horizontal dark 
box at RT. The tissue was then incubated with 100 µl of primary antibody / 
blocking solution (1:100 dilution) overnight at 4°C. The primary antibody Ki-67 
(1:100; Novacastra,U.K.), CD34 (1:100; Novusbio,NBP1-44407,EP373Y ) was 
carried out in this experiment. The next day the sections were washed three 
times for 3 min each in 1×PBS and then incubated in 100 µl each secondary 
antibody Rabbit (1:200,Vector Laboratories, Inc., Burlingame) / blocking 
solution for 1 hour at RT. The sections were then rinsed three times for 3 min 
with 1 × PBS, 100 µl of ABC reagent (Vectastain ABC Kit, Vector Laboratories) 
was applied to the tissue and incubated for one hour after the 
above-mentioned principle. Three times in 1 × PBS rinse each 300 ul freshly 
prepared Vector DAB substrates (peroxidase Substrate Kit DAB, Vector 
Laboratories) were applied to the fabric and waited up to 3 min until a brownish 
color was visible. Subsequently, the slides were immersed in distilled water to 
stop the DAB reaction. This was followed by counterstaining with hematoxylin 
for 1 minute and subsequent rinsing with water. Finally, the sliedes were rinsed 
in ascending alcohol series for dehydration (three min each in 40%, 75%, 95% 
and 100% ethanol) and for 6 min were immersed in xylene.  For the 
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quantification of Ki-67 staining, we use imagejsl.org online software to make 
the analysis. For the CD34 microvascular quantification we use MVD 
(microvascular density) assay, the MVD areas were quantitatively measured 
by Image-Pro plus 6.2.1 software (Media Cybernetics, Silver Spring, EUA). 
The final MVD of each sample was calculated by the ratio of the sum of the 
immunopositive areas and the sum of the total area. 
 
2.2.13 Statistical Analyses 
All the experiments were repeated 3 times. Data are presented as 
mean±standard deviations [39]. The results were analyzed using software 
Graphpad prism version 5.0 (GraphPad Software, San Diego, CA, USA) and 
SPSS Version 11.0 (SPSS, Chicago, USA). The tests include one-way 
ANNOVA analysis of variance and student´s t-test along with Bonferroni post 
test and paired and unpaired t-tests. The overall survival analysis using 
Kaplan-Meier curves were analysed by log rank test. For all tests, a P value of 
<0.05 was considered statistically significant. 
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3. Results 
3.1 Argyrin F (AF) treatment inhibits proliferation, migration, invasion 
and colony formation of human PDAC cell lines  
First, we determined the sensitivity of the KP3 and Panc-1 cell lines to AF 
treatment by WST-1 assay. Cells were submitted for 72hrs to a range of AF 
concentrations going from 0.001μg/ml to 100μg/ml. Panc-1 showed higher 
sensitivity to AF with a half maximal inhibitory concentration (IC50) equal to 
0.5μg/ml and KP3 exhibited lower (IC50 = 6μg/ml) (Figure.6). Thus, we 
continued with three different concentrations of AF for in vitro experiments: 
0.5μg/ml, 2μg/ml and 6μg/ml. Next, cell proliferation assays showed AF 
treatment reduced the number of viable KP3 and Panc-1 cells in a dose and 
time dependent manner (Figure.7, Figure.8). The light-microscopic pictures 
were taken after 96hrs, respectively illustrate the inhibitory effect of AF on the 
growth of PDAC cell lines.  
 
The metastasis process of malignant neoplasms is due the ability of migration 
and invasion of malignant cells. Thus, we sought to explore the impact of AF 
on this process in KP3 and Panc-1 cells lines. First, we examined cell motility 
by employing wound healing assays in the presence or absence of AF. 24hrs 
after the scratch, cell migration into the wound was captured under the 
microscope at 10x magnification (Figure.9, Figure.10). For both KP3 and 
Panc-1 cells, significant inhibition of wound closure was seen with treatment of 
6μg/ml AF (p<0.05). In contrast, 80-90% wound healing was seen after 24hrs 
in all DMSO control cells. Thus, AF can effectively inhibit the migration of 
PDAC cells. Next, we tested cell invasion by using transwell chambers.  
PDAC cells were plated in wells of an invasion chamber in the presence of 
different drug concentrations compared to DMSO control and experiments 
were conducted in Material and Methods. As shown in Figure.11 and 
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Figure.12, the invasion of PDAC cells (KP3, Panc-1) was significantly reduced 
(p<0.05) upon treatment with AF, with reductions of up to 60% - 70% in the 
number of invading cells compared to the DMSO control group. In particular for 
KP3 cells, the concentration of 0.5μg/ml showed no significant difference 
compared to the DMSO control. Thus, treatment with AF has an anti-invasive 
effect on human PDAC cell lines. Finally, AF strongly inhibited the ability of 
both pancreatic cells to form colonies in soft agar compared to DMSO treated 
cells. (Figure.13, Figure.14). These experiments suggest that AF treatment 
can inhibit proliferation, migration, invasion and colony formation of human 
PDAC cell lines. Panc-1 cells showed overall stronger inhibitory effect under 
AF treatment compared to KP3 cells.  
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Figure.6 Argyrin F cytotoxicity 
(a) KP3 and (b) Panc-1 cells were treated for 72hrs with increasing concentrations of AF 
(0,001μg/ml to 100μg/ml). Cell viability was measured using WST-1 assay and DMSO was 
used as the control. 
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Figure.7 WST-1 assay: Dose-dependent inhibition of cell proliferation of KP3 by AF  
a. Representation of the proliferative growth of the respective treatments. Shown with mean 
values and standard deviations; b. Comparative presentation of the corresponding light 
microscopic images: 10x magnification 
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Figure.8 WST-1 assay: dose-dependent inhibition of cell proliferation of Panc-1 by AF  
a. Representation of the proliferative growth of the respective treatments. Shown with mean 
values and standard deviations; b. Comparative presentation of the corresponding light 
microscopic images: 10x magnification 
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Figure.9 Inhibition of cell migration on KP3 cell by AF treatment 
a. Wound healing experiments were done for KP3 cells cultured with DMSO and AF (0.5μg/ml, 
2μg/ml and 6μg/ml). The dotted lines and arrows are representing the edges of the wound. 
Photographs were taken at 0 and 24hrs under light microscope (10x magnification). b. The 
migration index was calculated as described in Materials and methods and plotted in bar 
graphs. Differences were considered as statistically when the p-value<0.05 and ns when 
p-value>0.05. The error bar represents standard deviation. 
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Figure.10 Inhibition of cell migration on Panc-1 cell by AF treatment 
a. Wound healing experiments were done for Panc-1 cells cultured with DMSO and AF 
(0.5μg/ml, 2μg/ml and 6μg/ml). The dotted lines and arrows are representing the edges of the 
wound. Photographs were taken at 0 and 24hrs under light microscope (10x magnification). b. 
The migration index was calculated as described in Materials and methods and plotted in bar 
graphs. Differences were considered as statistically when the p-value<0.05 and ns when 
p-value>0.05. The error bar represents standard deviation. 
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Figure.11 Inhibition of invasion on KP3 cell by AF treatment 
a. KP3 cells were treated as indicated previously for 48hrs to investigate the effect on 
invasiveness. The number of cells that invaded through the membrane was determined by 
light microscope (20x magnification). b. Invasion index was calculated as described in 
Materials and methods and plotted in bar graphs. Differences were considered as statistically 
when the p-value<0.05 and ns when p-value>0.05. The error bar represents standard 
deviation. 
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Figure.12 Inhibition of invasion on Panc-1 cell by AF treatment 
a. Panc-1 cells were treated as indicated previously for 48hrs to investigate the effect on 
invasiveness. The number of cells that invaded through the membrane was determined by 
light microscope (20x magnification). b. Invasion index was calculated as described in 
Materials and methods and plotted in bar graphs. Differences were considered as statistically 
when the p-value<0.05 and ns when p-value>0.05. The error bar represents standard 
deviation. 
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Figure.13 Inhibition of colony formation on KP3 cells by AF treatment 
a. KP3 cells were treated as indicated for 3 weeks under DMSO and AF (0.5μg/ml, 2μg/ml and 
6μg/ml). The numbers of colonies were determined by light microscope (10x magnification). b. 
The number of colonies were calculated when its diameter was >0.75cm and plotted in bar 
graphs. Differences were considered as statistically when the p-value<0.05 and ns when 
p-value>0.05. The error bar represents standard deviation. 
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Figure.14 Inhibition of colony formation on Panc-1 cells by AF treatment 
a. Panc-1 cells were treated as indicated for 3 weeks under DMSO and AF (0.5μg/ml, 2μg/ml 
and 6μg/ml). The numbers of colonies were determined by light microscope (10x 
magnification). b. The numbers of colonies were calculated when its diameter was >0.75cm 
and plotted in bar graphs. Differences were considered as statistically when the p-value<0.05 
and ns when p-value>0.05. The error bar represents standard deviation. 
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3.2 Argyrin F(AF) treatment induces considerable apoptosis compared to 
senescence in human PDAC cell lines 
In order to analyze whether AF treatment induces apoptosis in PDAC cells we 
first performed Annexin V and PI staining. We found that AF treatment induced 
considerable levels of apoptosis in these PDAC cell lines, with levels 
increasing drug dose, but only 6µg/ml of AF showed significant induction of 
apoptosis compared to DMSO control (p<0.05) (Figure.15). Higher induction of 
apoptosis up AF treatment was found in KP3 cells at 96hrs compared to 
Panc-1 cells (35% in KP3 and 16% in Panc-1).  
 
Senescence is regarded as a physiological response of cells to stress, 
including telomere dysfunction, aberrant oncogenic activation, DNA damage, 
and oxidative stress [54]. Thus, we analyzed senescence as a possible cell 
death mechanism induced by AF. Relative percentage of senescence cells 
was measured by senescence associated ß-galactosidase (SA-ß-Gal) activity 
assay in KP3 and Panc-1 cells. PDAC cells were treated with DMSO and AF 
for 48hrs. As shown in Figure.16 and Figure.17, Panc-1 cells induced 
maximum of 10% of senescent cells at 6µg/ml of AF treatment compared to 
DMSO control, KP3 cells showed maximum of 9% induction of senescent cells 
in relation to DMSO control at 2µg/ml of AF treatment. No senescence was 
observed at 96hrs upon AF treatment (data not shown). Therefore, our results 
indicate that AF treatment mainly induces apoptosis in PDAC cells. 
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Figure.15 AF treatment resulted in a considerable apoptosis for PDAC cells lines 
(a) KP3 cells and (B) Panc-1 cells treated with DMSO, or AF (0.5µg/ml, 2µg/ml, 6µg/ml) for 
48hrs and 96hrs, the apoptosis was quantified by staining with Annexin V and propidium 
iodide (PI) using flow cytometry. Differences were considered as statistically when the 
p-value<0.05 and ns when p-value>0.05. The error bar represents standard deviation. 
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Figure.16 AF treatment resulted in a partialy induction of celluar senescence for KP3 
cell 
a. KP3 cells were treated with DMSO, AF (0.5µg/ml, 2µg/ml, 6µg/ml) for 48h and senescence 
was quantified by SA-beta-gal staining. B. The senescence positive cells were counted and 
plotted in bar graph. Differences were considered as statistically significant when the p-value 
was < 0.05 and ns was when p-value>0.05. The error bar represents standard deviation. 
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Figure.17 AF treatment resulted in a partialy induction of celluar senescence for Panc-1 
cells 
a. Panc-1 cells were treated with DMSO, AF (0.5µg/ml, 2µg/ml, 6µg/ml) for 48h and 
senescence was quantified by SA-beta-gal staining. B. The senescence positive cells were 
counted and plotted in bar graph. Differences were considered as statistically significant when 
the p-value was < 0.05 and ns was when p-value>0.05. The error bar represents standard 
deviation. 
 
3.3 Argyrin F (AF) treatment partially impairs epithelial-mesenchymal 
transition (EMT) in human PDAC cell lines 
The epithelial-to-mesenchymal transition (EMT) is a process during which cells 
undergo a developmental switch from an epithelial phenotype to a 
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attenuate EMT in human PDAC cell lines we treated KP3 and Panc-1 cells 
with different AF concentrations (0.5µg/ml, 2µg/ml, 6µg/ml) for 48 and 96hrs. 
For KP3 cells, we observed that epithelial marker (E-cadherin) was down 
regulated after 24hrs and the effect was stable till 96 hrs. But the expression of 
mesenchymal marker (N-cadherin) remained unchanged. For Panc-1 cells, 
pharmacological treatment resulted in an increased expression of E-cadherin 
and decreased expression of N-cadherin in a time-dose-independent manner 
as assessed by Western Blot (Figure.18). The results suggested that AF 
treatment might not have direct impact on EMT in PDAC cells. 
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Figure.18 AF treatment partially impairs EMT in PDAC cell lines 
(a) KP3 and (b) Panc-1 cells were treated with DMSO and AF (0.5µg/ml, 2µg/ml, 6µg/ml) for 
48 and 96hrs. The expressions of EMT markers (E-cadherin and N-cadherin) were analyzed 
by western blot. β-actin was used as a loading control. 
 
3.4 The effect of AF treatment on p27kip1 and p21waf1/cip1 and on cell cycle 
distribution in human PDAC cell lines  
p27kip1 and p21waf1/cip1 are known to be important markers for cell cycle 
distribution [49]. Thus, we first checked the expression of of both of these 
markers p27kip1 and p21waf1/cip1 on protein level as assessed by Western Blot. 
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We found an effective upregulation of p27kip1 and p21waf1/cip1 under AF 
treatment compared to the respective DMSO controls in a 
time-dose-dependent manner in both PDAC cell lines (KP3, Panc-1) 
(Figure.19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.19 AF treatment showed stabilization effect on the expression of p27
kip1
 and 
p21
waf1/cip1
 levels in PDAC cell lines  
(a) KP3 and (b) Panc-1 cells were treated with DMSO and AF (0.5µg/ml, 2µg/ml, 6µg/ml) for 
48hrs and 96hrs. The expression of p27
kip1
 and p21
waf1/cip1
 were analyzed by western blot. 
β-actin was used as a loading control. 
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Subsequently, the effect of AF on the cell cycle distribution was examined. As 
shown in Figure.20, when exposed to AF treatment (0.5μg/ml, 2μg/ml, 6μg/ml), 
Panc-1 cells showed no increase in sub-G1 population at 48hrs (1.8%, 1.19%, 
1.64%) and 96hrs (1.93%, 1.75%, 2.14%) compared to DMSO (2.04%, 
1.98%). But for KP3 cells, we found a considerable increase in percentage of 
sub-G1 population as compared to DMSO (DMSO: 3.51%, 0.5μg/ml: 6.81%, 
2μg/ml 8.30%, 6μg/ml: 9.12%) at 96hrs (Shown in Figure.20-a). The effect of 
AF treatment on KP3 and Panc-1 cell cycle distribution is shown in Table.1. 
There were progressively more cells in G1-phase and fewer cells in S-phase at 
48hrs and 96hrs for Panc-1, indicating a complete G1/S phase arrest by AF 
treatment in a dose dependent manner. In contrast, KP3 cells showed no 
significant G1/S-phase arrest when exposed to AF treatment at 48hrs and 
96hrs (Figure.21). 
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Figure.20 Cell cycle analysis on PDAC cell lines by AF treatment 
(a) KP3 and (b) Panc-1 cells were treated with DMSO and AF (0.5µg/ml, 2µg/ml, 6µg/ml) for 
48hrs and 96hrs. Cell cycle profile was investigated by PI staining. Percentage of 
Sub-G1-phase population was calculated. 
 
48h DMSO 48h 0.5ug/ml 48h 2ug/ml 48h 6ug/ml 
96h DMSO 96h 0.5ug/ml 96h 2ug/ml 96h 6ug/ml 
a. 
48h DMSO 48h 0.5ug/ml 48h 2ug/ml 48h 6ug/ml 
96h DMSO 96h 0.5ug/ml 96h 2ug/ml 96h 6ug/ml 
b. 
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a. 
48h KP3 (%) Panc-1 (%) 
Treatment 
(μg/ml) 
G1 
phase 
S-phase 
G2/M 
phase 
G1 
phase 
S-phase 
G2/M 
phase 
DMSO 45.72 26.89 15.95 38.32 20.57 21.57 
0.5 50.24 19.17 14.49 33.81 21.7 12.09 
2 51.71 23.4 13.82 47.1 14.01 19.58 
6 53 18.91 20.32 53.02 11.23 20.86 
 
b. 
96h KP3 (%) Panc-1 (%) 
Treatment 
(μg/ml) 
G1 
phase 
S phase 
G2/M 
phase 
G1 
phase 
S phase 
G2/M 
phase 
DMSO 43.79 23.96 20.64 38.56 17.48 22.46 
0.5 52.32 20.42 16.73 44.23 18.48 19.58 
2 57.34 14.97 15.78 55.06 8.47 19.74 
6 56.42 19.59 11.12   72.06 1.52 18.95 
 
Table.1 Effect of AF treatment on KP3 and Panc-1 cell cycle distribution  
a. 48hrs exposure to DMSO and AF (0.5µg/ml, 2µg/ml, 6µg/ml). b. 96hrs exposure to DMSO 
and AF (0.5µg/ml, 2µg/ml, 6µg/ml).  
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Figure.21 AF treatment partially induces G1/S phase cell cycle arrest in PDAC cell lines 
KP3 and Panc-1 cells were treated with DMSO and AF (0.5µg/ml, 2µg/ml, 6µg/ml) for 48hrs 
and 96hrs. Cell cycle profile was investigated by PI staining. a. Representative bar graph for 
KP3 cells; b. Representative bar graph for Panc-1 cells. 
 
3.5 Both AF single and combinational (A+G) treatment inhibit tumor 
growth and prolong overall survival in KPC mice  
To analyze the in vivo effect of AF we used a genetically engineered PDAC 
(KPC) mouse model, (Pdx1-Cre; KrasG12D; p53Lox/+). We subjected a total of 18 
mice for survival analysis. Mice were treated intraperitoneally with AF 
(1mg/kg/body weight, Day1-Day3), combination of AF (1mg/kg/body weight 
Day1-Day3) + Gemcitabine (100mg/kg/body weight Day5) or vehicle starting 
at an age of 14-weeks as further mentioned in the Materials and Methods part. 
 
3.5.1 Survival experiment (tumor volume, body weight). 
Mice were treated with AF single and (AF+G) combinational treatment starting 
at 14-weeks. The treatment outcome of AF single and (AF+ G) combinational 
treatment was compared to vehicle (PBS) therapy. AF+G combinational 
a. b. 
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treatment showed longest survival with a median of 85 days life span as 
compared to vehicle group (p<0.05), which showed an average survival of only 
46 days (Figure.22-a). Single treatment with AF also showed a longer survival 
with a median of 56 days as compared to the vehicle group (46 days), but 
there was no significant difference between both groups.  
 
All mice were sacrificed at the end of this study when the critical illness was 
developed. As shown in Figure.22-b, AF single treatment and also in 
combination with G showed an effective reduction in tumor volume as 
compared to the vehicle group p<0.05. Additionally, significant decrease in 
pancreatic tumor volume was also macroscopically observed under all 
treatment groups (AF single, AF+G) as compared to the vehicle group 
(Figure.22-c). Furthermore, the body weight of mice in all groups was 
measured during the study (Figure.22-d). Both AF and AF+G groups showed 
stable body weight throughout the experiment. Altogether, AF as a single 
agent as well as in combination with G was safe and without side effects. 
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Figure.22 AF+G combinational treatment prolongs survival lifespan in PDAC and 
resulted in the reduction of tumor volume. 
a. Survival is extended by the combination treatment of AF and G (median survival vehicle 46 
days vs. 85 days with AF+G; p<0.05 n=6; vehicle [red], AF [blue], AF+G [green]). b. 
Quantification of tumor volume (n=6) c. Represents macroscopic pictures of tumors from 
vehicle, AF and AF+G combinational treatment group. Tissues were harvested at the end of 
the experiment. d. The body weight of mice in all the groups was measured throughout the 
course of the experiment. 
Ve
hi
cl
e
A
F
A
F+
G
0
500
1000
1500
2000
2500
3000
T
u
m
o
r 
V
o
lu
m
e
(m
m
³)
p<0.05
0 2 4 6 8 10 12 14 16
70
80
90
100
110
120
Vehicle
AF
AF+G
weeks
b
o
d
y
 w
e
ig
h
t 
re
m
a
in
in
g
(%
)
vehicle AF AF+G 
c. 
b. 
d. 
 75 
 
3.5.2 Analysis of metastasis incidence and tumor progression in vivo 
The metastasis incidences were shown in Table.2, 100% (6/6) ascites and 
66.7% (4/6) metastasis were observed in the vehicle group. In the AF group, 
ascites was observed in 66.7% (4/6) of mice and 16.7% (1/6) showed 
metastasis. In the combinational treatment group, 16.7% (1/6) had ascites and 
no metastasis were observed. The incidence of metastasis we oberved inculed 
liver and peritoneum. 
 
 Vehicle(n=6) AF (n=6) AF+G (n=6) 
Incidence of 
metastasis  
66.7% 16.7% 0% 
Ascites 100% 66.7% 16.7% 
 
Table.2 Metastasis incidence and ascites in KPC mice 
Metastasis included liver metastasis and peritoneal metastasis in this study.  
 
In order to elucidate the anti-tumor effect of AF single and AF+G combinational 
treatment on tumor progression, areas of PDAC were compared to the normal 
pancreatic tissue (Figure.23-a). We found that KPC mice treated with vehicle 
showed large PDACs without remaining normal pancreatic tissue (Figure.23). 
Mice treated by either AF or AF+G showed smaller PDAC (Figure.23-b). Thus, 
these results highlighted that AF single treatment or in combination with G 
effectively impair PDAC progression in vivo. Interestingly, we observed a 
significant amount of necrosis especially in the AF single treatment group 
(Figure.24). However, the combinational treatment (AF+G) did not result in 
different necrotic areas compared to the vehicle group. 
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Figure.23 AF and AF+G combinational treatment impaired PDAC progression in KPC 
mice 
a. Representative image of full tumors from vehicle, AF and AF+G combinational treatment 
groups. Dotted lines sketch out the tumor tissue, areas without lining represent normal 
pancreatic tissue. b. The graph illustrates the percentage of each pancreas occupied by the 
tumor in individual mice. Each symbol represents a mice and the horizontal line represents 
percentage of each group (n=6). 
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Figure.24 AF single treatment showed more necrosis in the KPC mouse in vivo 
a. Representative image of full tumors from vehicle, AF and AF+G combinational treatment 
groups. Dotted lines sketch out the necrotic area. b. Quantification of necrosis in the survival 
study. Differences were considered as statistically significant when the p-value was < 0.05. 
 
3.5.3 Analysis of Ki-67 and CD34 expression in in vivo PDAC tumors 
To analyze the in vivo drug treatment effect on cell proliferation, we performed 
Ki67 staining [55]. As shown in Figure.25, combinational treatment (AF+G) 
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resulted in an effective decrease of Ki-67 positive cells (5%) as compared to 
the vehicle group (16%) (p<0.05). Although, AF single treatment showed a 
decrease in Ki-67 staining but the results were not significant in comparison to 
the vehicle group.  
 
Angiogenesis is a proliferative process resulting in the development of new 
blood vessels from existing endothelial cells and occurs during reproduction, 
development and wound repair. Tumor angiogenesis is usually quantified as 
microvascular density (MVD). In the present study MVD was mainly assessed 
in highly vascularized tumor areas by using the pan-endothelial antibody, 
CD34 [56]. Many data has assumed that angiogenic activity is associated with 
the development and progression of some solid tumors and has an important 
prognostic value [57]. As shown in Figure.26, the MVD-CD34 score was 
significantly higher in the vehicle group in comparison to both AF single 
treatment and AF+G group (p<0.05). However, no significant difference was 
observed between the two treatment groups (AF, AF+G).  
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Figure.25 AF+G combinational treatment resulted in an anti-proliferative effect on in 
vivo tumors. 
a. Ki67 staining of pancreatic tumors from each treatment group (n=6, 10x and 20x 
magnification). b. Quantification of Ki67 staining in the tumor tissues(n=6), showing reduction 
in Ki67 positive cells following AF+G combinational treatment. Differences were considered as 
statistically significant when the p-value was < 0.05 and ns when p-value was >0.05. The error 
bar represents standard deviation. 
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Figure.26 AF+G combinational treatment inhibits the angiogenesis on in vivo tumors. 
a. Histological representative CD34 IHC-stained images for each group (vehicle, AF, AF+G, 
10x and 20x magnification). b. Quantification of MVD scores were plotted in bar graph. 
Differences were considered as statistically significant when the p-value was < 0.05 and ns 
when p-value was >0.05. The error bar represents standard deviation. 
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4. Discussion 
PDAC is an aggressive malignancy and currently the fourth leading cause of 
cancer related deaths in the US [58]. Although novel chemotherapies are 
available, there overall survival and the therapy response is still limited. In the 
quest for new targets for PDAC therapy, the proteasome and its inhibitors have 
been the focus of academic and industrial research [59]. Proteasome inhibitors 
have anti-cancer activity through a variety of cellular mechanisms, including 
anti-proliferative activity, induction of apoptosis, interference with cell-cycle 
progression, inhibition of angiogenesis, etc. In the present study, we study the 
new proteasome inhibitor Argyrin F (AF), which has been identified as a 
promising antitumor compound through its p27kip1 stabilization effect [52], on 
PDAC carcinogenesis. 
 
In vitro, we selected two human PDAC cell lines: KP3 and Panc-1 due to 
preliminary IC50 experiment under AF treatments. These two cell lines are from 
different origins: Panc-1 is a common available human PDAC cell line, cultured 
from a primary tumor without evidence of metastasis, in contrast KP3 is 
obtained from liver metastasis of a human pancreatic tumor. We found 
effective inhibition of cell proliferation in both Panc-1 and KP3 cells compared 
to their DMSO controls. However, Panc-1 cells demonstrated to be more 
sensitive to AF treatment after 96h compared to KP3 cells. Nickeleit et al. [51] 
have revealed the mechanism by which Argyrin A (the analogue of AF) 
influences tumor cell proliferation all depending on stabilization of p27kip1 and 
Zhang et al. [60] showed that up-regulating the expression of p21waf1/cip1 has 
an inhibitory effect on cell proliferation of Panc-1. Next, Bülow et al. [52] has 
shown that treatment with AF resulted in a dose-dependent expression of 
p27kip1 in SW-480 colon carcinoma cells.  
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In our study, we also observed a relative up-regulation of p27kip1 and 
p21waf1/cip1 expression in a time-dose-dependent manner under AF treatment 
for both cell lines by Western Blot. It is known that p27kip1 is one the most 
frequently deregulated tumor suppressor proteins in human cancers [46]. 
Decreased p27Kip1 levels have been correlated with tumor aggressiveness and 
poor patient survival [46];[48];[61]. Sarker et al. [62] reported that an oncogenic 
miRNA which targets p27kip1 can consequently up-regulate the expression of 
p27kip1, leading to the inhibition of cell proliferation and migration of PDAC cell 
lines (MiaPaCa-2, Panc-1 and BxPC3). Yadav et al. [63] reported that 
Gatifloxacin can induce p21waf1/cip1 and p27kip1 levels in PDAC cell lines 
(Panc-1, MiaPaCa-2) by causing S-phase arrest to perform its anti-tumor 
effect. Zhang et al. [64] and Katayose et al. [65] have revealed that p27kip1 
expression can also be correlated to the induction of apoptosis, but the exact 
mechanism of this correlation is not yet identified.  
 
As it was observed in the present study, KP3 cells demonstrated a gradually 
increased population of sub-G1-phase cells after 96hrs under AF treatment. 
This is consistent with the result that AF treatment also induced a considerable 
apoptosis on KP3 cell lines as compared to Panc-1 cells (96h: 34% vs 16%), 
which are in line with the p27kip1 expression levels and cell cycle profile. 
Importantly, not all tumor cells that were treated with AF in vitro underwent a 
considerable apoptosis; some instead underwent cell-cycle arrest. We found 
that AF treatment might exert the cytostatic effect on Panc-1 cells by arresting 
the cells in the G1/S-phase of the cell cycle profile, but KP3 cells did not show 
any cell cycle arrest under AF treatment. These results indicate that 
anti-proliferative effect of AF might behave differently on Panc-1 and KP3: 
Panc-1 mainly underwent cell-cycle arrest and KP3 mainly induced cell 
apoptosis.    
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Since we observed an up-regulation of p21waf1/cip1 and p27kip1 expression 
under AF treatment and p21waf1/cip1 is known as a senescence mediator of the 
death receptor, we next performed X-gal staining to investigate whether AF 
induces cell senescence in addition to apoptosis. Cellular senescence is 
defined as an irreversible form of cell cycle arrest. Campisi et al. [66] pointed 
out that two cell-cycle inhibitors that are often expressed by senescent cells 
are the cyclin-dependent kinase inhibitors: p21waf1/cip1 and p16INK4a. Park et al. 
[67] proved that all-trans retinoic acid can induce cellular senescence via 
upregulation of p16INK4a, p21waf1/cip1 and p27kip1, as the cyclin-dependent 
kinase inhibitors, resulting in a cell cycle arrest in G1-phase. Unfortunately, we 
could not correlate the expression level of p21waf1/cip1 and p27kip1 with the 
induction of senescence in our tested cell lines. Both of our cell lines failed to 
show high induction of senescence in contrary to the immunoblots showing 
considerable upregulation of both the markers (p21waf1/cip1 and p27kip1). This 
might indicate that AF treatment mainly induces apoptosis and less 
senescence, but additional experiments are required in order to confirm the 
ultimate cell death mechanism induced upon AF treatment. 
 
In the recent years, accumulated evidence has suggested that EMT plays a 
critical role for PDAC development associated with invasion, migration, early 
metastasis and chemo-resistance [42]. Moreover, EMT has been 
demonstrated in human PDAC specimens, and tumorigenic cells with 
mesenchymal features to show a positive correlation with high-grade PDAC 
[68]. Specifically, PDAC with more mesenchymal features resulted in a worse 
survival and increased numbers of metastasis. We analyzed two EMT-markers 
in the present study: E-cadherin and N-cadherin. E-cadherin is expressed in 
epithelial cells, and its expression is decreased during EMT process in 
embryonic development, tissue fibrosis, and cancer. Moreover, loss of 
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E-cadherin function promotes EMT and is associated with advanced PDAC 
[69];[70]. N-cadherin is down regulated at other sites of EMT, including the 
neural crest and somites. N-cadherin used to monitor the progress of EMT 
during embryonic development and cancer progression [42]. We found that AF 
treatment resulted in an in vitro inhibition of migration and invasion in PDAC 
cells. For Panc-1 cells we observed a time-dose-dependent decrease of 
mesenchymal marker (N-cadherin) and increase of epithelial marker 
(E-cadherin). On the other hand, the EMT markers were unchanged for KP3 
cells. Since we do not see any change in EMT expression in KP3 cells after AF 
treatment this might correlate with the different background of the two tested 
cell lines. Panc-1 cells after AF treatment show relatively effective inhibition of 
mesenchymal markers and also of invasion and migration. This explains that 
AF influences EMT process in Panc-1 cells but not much for KP3 cells. The 
difference in drug efficacy regarding EMT can be attributed to various reasons 
like different metastasis backgrounds of the cell lines which might impact 
differently to the ultimate effectiveness of the drug. Taken together, these 
results suggest that AF treatment selectively inhibits EMT in PDAC cells. 
 
For the in vivo part of our study, we used a well-established (KPC) mouse 
model: Pdx1-Cre; LSL-KrasG12D/+; p53Lox/+ which recapitulate human PDAC 
progression [53]; [71]. KPC mouse has a dramatically shortened median 
survival of approximately 5 months and it starts to develop advanced PDAC 
from 2 to 3 months onwards. Moreover, the natural microenvironment of the 
pancreas is maintained in this mouse model [53]. In our study we commenced 
the treatment at 14 weeks of age, at this timepoint KPC mice have precursor 
lesions and already show small PDAC formation [53]. Most significantly, AF in 
combination with G significantly inhibited pancreatic carcinogenesis in KPC 
mice. AF and AF+G treated animals significantly reduced incidence of 
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metastasis and the treatment regime was well tolerated in all experimental 
groups. This study also demonstrated that AF+G combinational treatment 
showed significant anti-proliferative effect as seen by reduced Ki-67 
expression in PDAC tumors.  
 
It is known that angiogenic activity is associated with the development and 
progression of PDAC and has an important prognostic value [57]. Hiroshima, 
et al. [72] showed that tumor-targeting Salmonella typhimurium A1-R in 
combination with anti-angiogenesis therapy (Bevacizumab + G) can reduce 
the xenograft tumor volume. In addition, Huang et al. [73] showed that Embelin 
inhibiting Akt and Sonic hedgehog pathway can inhibit pancreatic tumor 
growth by regulating angiogenesis and metastasis. Controversially, some 
research groups showed that PDAC is hypovascular in both humans and KPC 
mice, so tumor progression is thought to thrive without the requirement for 
excessive angiogenesis [74]. Suzuki et al. [75] demonstrated that combination 
of NF-κ b inhibitor and G can exert anti-tumor effects by inhibiting 
angiogenesis. In the present study, our results showed a reduction of tumor 
volume as well as the MVD (micro vessel density) score under AF and AF+G 
combinational treatment. These results relate to the study of Bülow L et al. [52] 
and showed that AF leads to a faster destruction of blood vessels than Argyrin 
A. Our results indicate that the combinational treatment of AF+G can inhibit the 
tumor growth by regulating angiogenesis and this might be a potential down 
staging approach for patients with unresectable lesion due to a smaller tumor 
volume. Moreover, we observed a significant amount of necrosis only in the AF 
single treatment group, but not in the combinational treatment group. Unlike 
tumor core necrosis, which is commonly observed in xenograft tumors, in KPC 
tumors combinational treatment induced necrosis that occurred in patches 
scattered throughout the tumor. In the present study, we found no correlation 
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between final tumor volume and necrosis or treatment length and necrosis, 
Cook et al. also showed similar results in KPC mouse model treated by 
gamma secretase inhibitor and gemcitabine [76]. 
 
The scarcity of endothelial fenestrations and open interendothelial junctions in 
treatment-naive KPC tumors stands in contrast to observations in xenografts, 
allografts and some spontaneous tumor models [77]. Some ultrastructural 
changes may permit access to therapeutic agents [78], their absence may 
contribute towards delivery inefficiency in the KPC tumors and explain the 
differential chemotherapeutic sensitivities between spontaneous tumors and 
other models. According to Olive et al. [71], KPC mice demonstrate innate 
resistance to G, so they suggest that inhibition of Hedgehog signaling can 
enhance delivery of G in KPC mice. Consistent with this study, combination of 
nab-paclitaxel and gemcitabine can also improve G delivery to pancreatic 
tumor showing an increased intratumoral level of G [79]. In the present study, 
AF+G combinational treatment resulted in a longer median survival and 
smaller tumor volume as well as reduced tumor cell proliferation, it indicates 
that AF might enhance Gemcitabine drug delivery in KPC mice.  
 
In conclusion, our findings indicated that AF treatment resulted in an inhibition 
of cell proliferation, migration, invasion and colony formation in PDAC cell lines. 
AF therapy induced a considerable amount of apoptosis and partially 
senescence in the tested PDAC cell lines in a dose-time-dependent manner. 
AF induced a gradually increasing population of cells in sub-G1-phase for KP3 
cells and also resulted in a G1/S-phase arrest on Panc-1 cells. AF treatment 
showed considerable inhibition of EMT in Panc-1 cells but not in KP3 cells. 
Most importantly, combinational treatment by AF+G showed prolonged 
survival and caused significant tumor reduction by inhibiting tumor cell 
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proliferation and angiogenesis. Taken together, AF in combination with G 
might be a new and promising therapeutic approach for patients with PDAC. 
but further studies are needed to validate our experimental findings. 
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5. Summary 
PDAC is the fourth most common cause of cancer death in the US and Europe. 
Current systemic chemotherapies are limited and new drugs are needed to 
improve survival. In the present study, we have analyzed in vitro (KP3, Panc-1) 
and in vivo (Pdx1-Cre; LSL-KrasG12D; p53 lox/+) the antitumor effect of the 
proteasome inhibitor Argyrin F (AF) single and in combination with 
Gemcitabine (AF+G). In vitro, AF therapy induced a dose-and time-dependent 
growth inhibition of KP3 and Panc-1 cells. Moreover, AF treatment resulted in 
an inhibition of migration, invasion and colony formation in PDAC cell lines. AF 
therapy induced a considerable amount of apoptosis and partially senescence 
in the tested PDAC cell lines in a dose-and time-dependent manner. 
Furthermore, cell cycle profile analysis showed that AF induced a gradually 
increasing population of cells in sub-G1-phase for KP3 cells and also resulted 
in a G1/S-phase arrest on Panc-1 cell. AF treatment showed considerable 
inhibition of EMT in Panc-1 cells but not in KP3 cells. In vivo, most importantly, 
combinational treatment by AF+G showed prolonged survival and caused 
significant tumor reduction. Less incidences of metastasis and ascites was 
observed after AF single and AF+G treatment. Expression of both the markers 
ki67 and CD34  showed reduced expression in the treament groups (AF, 
AF+G). AF and AF+G treatment regimes were well tolerated by all the animals 
used in the study. In conclusion, our work demonstrates that treatment with AF 
can successfully inhibit the growth of PDAC in vitro and in vivo. Especially, AF 
in combination with G might be a new and promising therapeutic approach for 
patients with PDAC, but further studies are needed to validate our findings. 
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6. Zusammenfassung 
Das Pankreaskarzinom (PDAC) gehört in den USA und Europa zu der 
vierthäufigsten Ursache an einem Malignom zu versterben. Aktuelle 
systemische Chemotherapien sind limitiert und es werden dringend neue 
Substanzen gesucht um das Überleben zu verbessern. In der vorliegenden 
Arbeit haben wir in vitro (KP3, Panc-1) und in vivo (Pdx1-Cre; LSL-KrasG12D; 
p53 lox/+) die anti-tumoröse Eigenschaft des Proteasom-Inhibitors Argyrin F (AF) 
als Monotherapie und in Kombination mit Gemcitabine (AF+G) untersucht. In 
vitro konnte die AF Therapie eine Dosis- und Zeit-abhängige Inhibition von 
KP3 und Panc-1 Zellen erreichen. Außerdem führte die AF Therapie zu einer 
Inhibition der Migration, Invasion und Kolonie-Formation. Ferner induzierte die 
AF Applikation einen Dosis- und Zeit-abhängigen Zelltod und führte zur 
Senescence. Die Analyse des Zellzyklus-Profils ergab unter Therapie für KP3 
Zellen eine erhöhte Population in der Sub-G1-Fraktion und für Panc-1 Zellen in 
der G1/S-Fraktion. AF führte dabei nur zu einer Inhibition der epithelialen 
mesenchymalen Transition (EMT) bei den Panc-1 Zellen. In vivo, erzielte die 
Kombinationstherapie (AF+G) ein verlängertes Überleben und erreichte eine 
signifikante Tumorverkleinerung. Sowohl AF als auch AF+G führten zu einer 
Abnahme von Aszites und Metastasen. Auch die Expression von Ki67 und 
CD34 konnten mit der Mono- und Kombinationstherapie reduziert werden. Alle 
Therapieregime waren im Mausmodell gut verträglich. Wir konnten somit 
erfolgreich demonstrieren, dass eine Therapie mit AF in vitro und in vivo das 
Wachstum von PDAC Zellen inhibieren kann. Vor allem die Kombination 
AF+G könnte somit eine neue und erfolgsversprechend Therapiemöglichkeit 
für Patienten mit PDAC darstellen, aber weitere Studien sind erforderlich um 
unsere Ergebnisse zu validieren.  
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